Tibet Rhodiola Pharmaceutical Holding Co is a China-based company mainly engaged in the business of pharmaceutical manufacturing and pharmaceutical trading. The Company operates two segments, including the Pharmaceutical Manufacturing segment and the Pharmaceutical Trading segment. The Company mainly produces and sells capsules, biological preparations, granules, film coatings, and others. The Company's main products involve cardiovascular and cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds and other fields. The Company mainly conducts businesses within the domestic market.

Employees

671

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	36.80 ¥	+0.96%	2,507,984
26-06-17	36.45 ¥	-0.63%	1,787,187
26-06-16	36.68 ¥	-1.37%	2,317,646
26-06-15	37.19 ¥	+1.64%	3,931,403
26-06-12	36.59 ¥	+3.63%	5,878,256

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2026-06-18			5-day change	1st Jan Change
36.80 ^CNY	+0.96%		+0.57%	-13.51%

05-08	Tibet Rhodiola Pharmaceutical Holding's board elects chairman	RE
04-28	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	11.71B 1.73B 1.51B 1.4B 1.31B 2.45B 163B 2.47B 16.58B 6.43B 80.38B 6.5B 6.36B 279B	P/E 2024	11.3x	P/E 2025	14.6x
Enterprise Value	9.11B 1.35B 1.17B 1.09B 1.02B 1.91B 127B 1.92B 12.89B 4.99B 62.48B 5.05B 4.94B 217B	EV / Sales 2024	3.4x	EV / Sales 2025	3.72x
Free-Float	39.36%	Yield 2024	5.3%	Yield 2025	4.13%

05-08	Tibet Rhodiola Pharmaceutical Holding's board elects chairman	RE
04-28	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.	CI
03-13	Tibet Rhodiola Pharmaceutical Logs 11% Decline in 2025 Profit, Revenue Up 6%	MT
03-12	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-05	Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025.	CI
12-18	Tibet Rhodiola Pharmaceutical Holding Co. announces an Equity Buyback.	CI
12-17	Tibet Rhodiola Pharmaceutical Holding Co. authorizes a Buyback Plan.	CI
25-10-30	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-29	Ruizheng Gene Co., Ltd. announced that it has received $75 million in funding from China Medical System Holdings Limited, Tibet Rhodiola Pharmaceutical Holding Co.	CI
25-08-26	Accuredit Therapeutics Us Limited announced that it expects to receive $75 million in funding from TopRidge Pharma Limited, Cms Medical Venture Investment (HK) Limited, Tibet Rhodiola Pharmaceutical Holding Co., Shenzhen Kangzhe Pharmaceutical Co., Ltd.	CI
25-08-26	Accuredit announced that it has received $75 million in funding from Tibet Rhodiola Pharmaceutical Holding Co., Shenzhen Kangzhe Pharmaceutical Co., Ltd.	CI
25-08-15	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

1 day	+0.96%
1 week	+0.57%
Current month	-4.51%
1 month	-10.31%
3 months	-13.25%
6 months	-13.31%
Current year	-13.51%

Tibet Rhodiola Pharmaceutical Holding Co. Stock

Stocks

600211

CNE000000ZW7

Pharmaceuticals

Valuation: Tibet Rhodiola Pharmaceutical Holding Co.

Chart: Tibet Rhodiola Pharmaceutical Holding Co.

Latest news : Tibet Rhodiola Pharmaceutical Holding Co.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Rhodiola Pharmaceutical Holding Co.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	35.96	37.38
1 month	34.92	40.55
Current year	34.92	46
1 year	34.92	57.98
3 years	26.95	57.98
5 years	22.73	57.98
10 years	13.54	140.05

Manager	Title	Age	Since
Yuan Dong Guo CEO	Chief Executive Officer	56	2014-11-19
Jun Chen DFI	Director of Finance/CFO	48	2019-10-24
Li Li Wen IRC	Investor Relations Contact	46	-

Director	Title	Age	Since
Da Bin Chen CHM	Chairman	70	2015-01-07
Yu Cheng Zhou BRD	Director/Board Member	44	2015-01-07
Yuan Dong Guo BRD	Director/Board Member	56	2015-01-07

	2024	2025
Net sales	2.81B 415M 362M 335M 313M 588M 39.13B 591M 3.97B 1.54B 19.26B 1.56B 1.52B 66.87B	2.98B 440M 384M 356M 333M 624M 41.56B 628M 4.22B 1.64B 20.46B 1.65B 1.62B 71.04B
Net income	1.05B 155M 135M 125M 117M 220M 14.66B 222M 1.49B 577M 7.21B 583M 571M 25.05B	938M 139M 121M 112M 105M 196M 13.08B 198M 1.33B 514M 6.44B 520M 509M 22.35B
Net Debt	-2.35B -347M -303M -281M -263M -493M -32.78B -495M -3.33B -1.29B -16.13B -1.3B -1.28B -56.02B	-2.61B -385M -336M -311M -291M -546M -36.37B -550M -3.69B -1.43B -17.9B -1.45B -1.42B -62.16B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.	+0.96%	+0.57%	+2.08%	-11.00%	1.73B
ELI LILLY AND COMPANY	-1.21%	-3.04%	+44.03%	+143.07%	980B
JOHNSON & JOHNSON	-2.48%	-5.18%	+52.47%	+39.15%	550B
ABBVIE INC.	-2.14%	-4.94%	+16.83%	+57.08%	382B
ROCHE HOLDING AG	+0.25%	-3.09%	+23.33%	+16.04%	316B
ASTRAZENECA PLC	+0.61%	-1.69%	+27.35%	+13.73%	272B
NOVARTIS AG	+0.22%	-3.10%	+24.67%	+30.49%	268B
NOVO NORDISK A/S	+4.59%	+1.98%	-38.43%	-46.26%	199B
AMGEN INC.	-1.19%	-4.95%	+16.68%	+47.69%	182B
GILEAD SCIENCES, INC.	-1.35%	-1.46%	+14.06%	+59.26%	154B
Average	-0.17%	-2.66%	+18.31%	+34.93%	330.41B
Weighted average by Cap.	-0.78%	-3.67%	+29.47%	+63.27%